MA43733A - Composés cinnolin-4-amine et leur utilisation pour traiter le cancer - Google Patents

Composés cinnolin-4-amine et leur utilisation pour traiter le cancer

Info

Publication number
MA43733A
MA43733A MA043733A MA43733A MA43733A MA 43733 A MA43733 A MA 43733A MA 043733 A MA043733 A MA 043733A MA 43733 A MA43733 A MA 43733A MA 43733 A MA43733 A MA 43733A
Authority
MA
Morocco
Prior art keywords
cinnolin
amine compounds
treat cancer
cancer
treat
Prior art date
Application number
MA043733A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA43733A publication Critical patent/MA43733A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
MA043733A 2016-03-21 2017-03-20 Composés cinnolin-4-amine et leur utilisation pour traiter le cancer MA43733A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662310883P 2016-03-21 2016-03-21

Publications (1)

Publication Number Publication Date
MA43733A true MA43733A (fr) 2018-11-28

Family

ID=58361025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043733A MA43733A (fr) 2016-03-21 2017-03-20 Composés cinnolin-4-amine et leur utilisation pour traiter le cancer

Country Status (18)

Country Link
US (1) US20190099421A1 (fr)
EP (1) EP3433251A1 (fr)
JP (1) JP2019512512A (fr)
KR (1) KR20180127419A (fr)
CN (1) CN108884084A (fr)
AR (1) AR107937A1 (fr)
AU (1) AU2017237394A1 (fr)
BR (1) BR112018068347A2 (fr)
CA (1) CA3017035A1 (fr)
CO (1) CO2018010951A2 (fr)
DO (1) DOP2018000197A (fr)
IL (1) IL261648A (fr)
MA (1) MA43733A (fr)
MX (1) MX2018011283A (fr)
PE (1) PE20181895A1 (fr)
SG (1) SG11201806982PA (fr)
TW (1) TW201808939A (fr)
WO (1) WO2017162605A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111344293A (zh) * 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
US20210353614A1 (en) * 2018-03-14 2021-11-18 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
CA3111994A1 (fr) 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one servant de modulateurs selectifs de la kinase ataxie telangiectasie (atm) mutee et utilisat ions associees
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
WO1997032856A1 (fr) 1996-03-05 1997-09-12 Zeneca Limited Derives de 4-anilinoquinazoline
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
WO2012101062A1 (fr) 2011-01-28 2012-08-02 Novartis Ag Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations
BR112013030095A2 (pt) * 2011-05-23 2019-09-24 Elan Pharm Inc inibidores de atividade de lrrk2 cinase
NO2714752T3 (fr) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
JP2019512512A (ja) 2019-05-16
MX2018011283A (es) 2019-05-27
CN108884084A (zh) 2018-11-23
PE20181895A1 (es) 2018-12-11
CO2018010951A2 (es) 2018-10-22
BR112018068347A2 (pt) 2019-01-15
WO2017162605A1 (fr) 2017-09-28
AR107937A1 (es) 2018-06-28
TW201808939A (zh) 2018-03-16
KR20180127419A (ko) 2018-11-28
AU2017237394A1 (en) 2018-11-01
US20190099421A1 (en) 2019-04-04
IL261648A (en) 2018-10-31
EP3433251A1 (fr) 2019-01-30
CA3017035A1 (fr) 2017-09-28
DOP2018000197A (es) 2018-10-15
SG11201806982PA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA49144A (fr) Polythérapies pour le traitement du cancer
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA43968A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA43364A (fr) Composés d&#39;alcènes tétrasubstitués et leur utilisation
MA45613A (fr) Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
MA43284A (fr) Composés et leurs méthodes d&#39;utilisation
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
KR20180084772A (ko) 암 치료를 위한 조합 치료법
MA44874A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type ii
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA45113A (fr) Composés mic-1 et leur utilisation
MA45406A (fr) Inhibiteurs d&#39;ezh2 pour traiter le cancer
MA43570A (fr) Thérapie génique pour traiter l&#39;hypercholestérolémie familiale
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
HK1259445A1 (zh) 治療癌症的組合